-
公开(公告)号:US07615618B2
公开(公告)日:2009-11-10
申请号:US11170798
申请日:2005-06-29
CPC分类号: C12N15/111 , C07H19/04 , C07H19/12 , C07H19/16 , C07H19/167 , C07H19/173 , C07H21/02 , C12N15/1136 , C12N15/1137 , C12N2310/14 , C12N2310/312 , C12N2320/51
摘要: One aspect of the present invention relates to a ribonucleoside substituted with a phosphonamidite group at the 3′-position. In certain embodiments, the phosphonamidite is an alkyl phosphonamidite. Another aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate, hydroxylamine, hydroxylhydrazinyl, amide, and carbamate linkages. In certain embodiments, the non-phosphate linkage is a phosphonate linkage. In certain embodiments, a non-phosphate linkage occurs in only one strand. In certain embodiments, a non-phosphate linkage occurs in both strands. In certain embodiments, a ligand is bound to one of the oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, a ligand is bound to both of the oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate, hydroxylamine, hydroxylhydrazinyl, amide, and carbamate linkages. In certain embodiments, the non-phosphate linkage is a phosphonate linkage. In certain embodiments, a ligand is bound to the oligonucleotide strand. In certain embodiments, the oligonucleotide comprises at least one modified sugar moiety.
摘要翻译: 本发明的一个方面涉及在3'-位被亚磷酰胺基取代的核糖核苷。 在某些实施方案中,亚磷酰胺是烷基亚磷酰胺。 本发明的另一方面涉及包含至少一种非磷酸键的双链寡核苷酸。 代表性的非磷酸酯键包括膦酸酯,羟胺,羟基肼基,酰胺和氨基甲酸酯键。 在某些实施方案中,非磷酸酯键是膦酸酯键。 在某些实施方案中,非磷酸酯键仅出现在一条链中。 在某些实施方案中,在两条链中都发生非磷酸连接。 在某些实施方案中,配体与包含双链寡核苷酸的寡核苷酸链之一结合。 在某些实施方案中,配体与包含双链寡核苷酸的两条寡核苷酸链结合。 在某些实施方案中,寡核苷酸链包含至少一个修饰的糖部分。 本发明的另一方面涉及包含至少一种非磷酸键的单链寡核苷酸。 代表性的非磷酸酯键包括膦酸酯,羟胺,羟基肼基,酰胺和氨基甲酸酯键。 在某些实施方案中,非磷酸酯键是膦酸酯键。 在某些实施方案中,配体与寡核苷酸链结合。 在某些实施方案中,寡核苷酸包含至少一个修饰的糖部分。
-
52.
公开(公告)号:US20090239814A1
公开(公告)日:2009-09-24
申请号:US12328528
申请日:2008-12-04
IPC分类号: A61K31/715 , C07H17/02 , C12N5/06
CPC分类号: A61K47/28 , A61K31/70 , A61K31/7004 , A61K31/7052 , A61K31/7088 , A61K31/713 , A61K47/16 , A61K47/22 , A61K47/543 , A61K47/549 , A61K47/60 , A61K48/00 , C07H21/02 , Y02A50/385 , Y02A50/411 , Y02A50/467 , Y02P20/55
摘要: The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(RN) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-Linker-OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z′)(Z″)-formula (I), —P(Z′)(Z″)— or -Linker-R; R is LG, -Linker-LG, or has the structure shown below: LG is independently for each occurrence a carbohydrate, e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide; RN is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; and Z′, Z″, Z′″ and Z″″ are each independently for each occurrence O or S.
摘要翻译: 本发明提供包含至少一个式(I)亚基的iRNA试剂:其中:A和B各自独立地为O,N(RN)或S; X和Y各自独立地为H,OH,羟基保护基,磷酸基,磷酸二酯基,活化磷酸酯基,活化亚磷酸酯基,亚磷酰胺,固体载体,-P(Z')( Z')(Z“)O - 寡核苷酸,脂质,PEG,类固醇,亲脂体,聚合物,-P(Z')(Z”)O (Z')(Z“) - (Z”)(Z“)(Z”)(Z“)(Z”) (Z“) - 或-Linker-R; R是LG,-Linker-LG,或具有如下结构:每次出现LG独立为碳水化合物,例如单糖,二糖,三糖,四糖,寡糖,多糖; 乙烯基,丙基,异丙基,丁基或苄基各自独立地为N, Z',Z“,Z”“和Z”“各自独立地为O或S.
-
公开(公告)号:US07582744B2
公开(公告)日:2009-09-01
申请号:US11200703
申请日:2005-08-10
CPC分类号: C12N15/113 , A61K31/7088 , A61K31/713 , A61K47/54 , A61K47/543 , A61K47/551 , A61K47/554 , C07F9/06 , C12N15/111 , C12N15/87 , C12N2310/113 , C12N2310/14 , C12N2310/351 , C12N2310/3515 , C12N2320/32 , C12N2320/51
摘要: This invention relates composition and methods for making and using chemically modified oligonucleotides agents for inhibiting gene expression.
摘要翻译: 本发明涉及用于制备和使用化学修饰的寡核苷酸抑制基因表达的组合物和方法。
-
公开(公告)号:US09512164B2
公开(公告)日:2016-12-06
申请号:US13382353
申请日:2010-07-07
IPC分类号: C12N5/02 , C12N15/113 , C07H21/02 , C07H21/04
CPC分类号: C12N15/113 , C07H21/02 , C07H21/04 , C12N2310/14 , C12N2310/344
摘要: Modified nucleic acids are described herein, including pharmaceutical compositions comprising the modified nucleic acids, and methods of using the modified nucleic acids.
摘要翻译: 本文描述了修饰的核酸,包括包含修饰的核酸的药物组合物,以及使用经修饰的核酸的方法。
-
公开(公告)号:US08927513B2
公开(公告)日:2015-01-06
申请号:US13382346
申请日:2010-07-07
IPC分类号: A01N43/04 , C07H19/11 , C07H19/213
CPC分类号: C12N15/113 , C07H19/10 , C07H19/11 , C07H19/20 , C07H19/213 , C12N2310/11
摘要: The present invention provides nucleosides and oligonucleotides comprising a 5′ phosphate mimics of formula (IVc) or (Vc). One aspect of the present invention relates to modified nucleosides and oligonucleotides comprising such dinucleotide of formula (Ia). Another aspect of the invention relates to a method of inhibiting the expression of a gene in call, the method comprising (a) contacting an oligonucleotide of the invention with the cell; and (b) maintaining the cell from step (a) for a time sufficient to obtain degradation of the mRNA of the target gene.
摘要翻译: 本发明提供了包含式(IVc)或(Vc)的5'磷酸酯模拟物的核苷和寡核苷酸。 本发明的一个方面涉及包含式(Ia)的二核苷酸的修饰核苷和寡核苷酸。 本发明的另一方面涉及一种抑制基因表达的方法,所述方法包括(a)使本发明的寡核苷酸与细胞接触; 和(b)将来自步骤(a)的细胞维持足以获得靶基因的mRNA降解的时间。
-
公开(公告)号:US20130317080A1
公开(公告)日:2013-11-28
申请号:US13822441
申请日:2011-09-14
申请人: Kallanthottathil G. Rajeev , Tracy Zimmermann , Muthiah Manoharan , Martin Maier , Kevin Fitzgerald
发明人: Kallanthottathil G. Rajeev , Tracy Zimmermann , Muthiah Manoharan , Martin Maier , Kevin Fitzgerald
IPC分类号: C12N15/113
CPC分类号: C12N15/113 , C12N15/111 , C12N2310/14 , C12N2310/315 , C12N2310/322 , C12N2310/343 , C12N2310/346 , C12N2310/351 , C12N2310/3515 , C12N2320/32 , C12N2320/52 , C12N2310/3533
摘要: The present invention provides effective motifs for RNA agents conjugated to at least one ligand, which are advantageous for the in vivo delivery of iRNA duplex agents. Additionally, the present invention provides methods of making these compositions, as well as methods of introducing these iRNA duplex agents into cells using these compositions, e.g., for the treatment of various disease conditions.
摘要翻译: 本发明提供了与至少一种配体缀合的RNA试剂的有效基序,其有利于iRNA双链体的体内递送。 此外,本发明提供了制备这些组合物的方法,以及使用这些组合物将这些iRNA双链体引入细胞的方法,例如用于治疗各种疾病状况。
-
公开(公告)号:US20130129785A1
公开(公告)日:2013-05-23
申请号:US13697229
申请日:2011-05-10
IPC分类号: A61K47/18 , C07C229/12 , C07C233/38 , A61K31/7088 , C07C271/12 , C07C275/20 , C07C271/64 , C07C219/08 , C07C237/06
CPC分类号: A61K47/18 , A61K9/1272 , A61K9/1278 , A61K31/7088 , C07C219/08 , C07C229/12 , C07C233/38 , C07C237/06 , C07C271/12 , C07C271/64 , C07C275/20 , C12N15/88
摘要: A lipid particle can include a cationic lipid. Synthesis of the cationic lipid can include a ylide-based reaction, such as a Wittig reaction or sulfur ylide reaction. In some cases, the synthesis can also include a Michael addition or a related addition reaction.
摘要翻译: 脂质颗粒可以包括阳离子脂质。 阳离子脂质的合成可以包括基于叶立德的反应,例如Wittig反应或硫叶立德反应。 在某些情况下,合成还可以包括迈克尔加成或相关的加成反应。
-
公开(公告)号:US08404862B2
公开(公告)日:2013-03-26
申请号:US12497262
申请日:2009-07-02
IPC分类号: C07F9/06
CPC分类号: C12N15/113 , A61K31/7088 , A61K31/713 , A61K47/54 , A61K47/543 , A61K47/551 , A61K47/554 , C07F9/06 , C12N15/111 , C12N15/87 , C12N2310/113 , C12N2310/14 , C12N2310/351 , C12N2310/3515 , C12N2320/32 , C12N2320/51
摘要: This invention relates composition and methods for making and using chemically modified oligonucleotides agents for inhibiting gene expression.
-
公开(公告)号:US20130018085A1
公开(公告)日:2013-01-17
申请号:US13620212
申请日:2012-09-14
申请人: Antonin de Fougerolles , Maria Frank-Kamenetsky , Muthiah Manoharan , Kallanthottathil G. Rajeev , Philipp Hadwiger
发明人: Antonin de Fougerolles , Maria Frank-Kamenetsky , Muthiah Manoharan , Kallanthottathil G. Rajeev , Philipp Hadwiger
IPC分类号: A61K31/713 , A61P35/00 , A61P27/02 , C12N5/071 , C07H21/02
CPC分类号: C12N15/1136 , A61K9/0019 , A61K31/7088 , A61K31/712 , A61K31/713 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/549 , A61K47/551 , A61K47/60 , A61K48/00 , C07K14/475 , C12N2310/14 , C12N2310/3515 , C12N2310/533 , C12N2320/30 , C12N2320/32
摘要: The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor (VEGF), such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.
-
公开(公告)号:US08344125B2
公开(公告)日:2013-01-01
申请号:US12619382
申请日:2009-11-16
CPC分类号: C12N15/111 , A61K47/554 , C12N2310/14 , C12N2310/323 , C12N2310/344 , C12N2310/3515 , C12N2320/51
摘要: The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a carbohydrate; or a steroid, e.g., cholesterol, which is optionally substituted with at least one carbohydrate. is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.
摘要翻译: 本发明涉及iRNA试剂,其优选包括其中核糖部分被除核糖以外的部分替代的单体。 包含这样的单体可以允许调节其引入其中的iRNA试剂的性质,例如通过使用非核糖部分作为配体或其他实体例如碳水化合物的点; 或类固醇,例如胆固醇,其任选被至少一种碳水化合物取代。 是直接或间接地束缚着。 本发明还涉及制备和使用这种修饰的iRNA试剂的方法。
-
-
-
-
-
-
-
-
-